Repligen shares surge as bioprocessing firm beats revenue expectations

Published 29/07/2025, 13:46
Repligen shares surge as bioprocessing firm beats revenue expectations

Investing.com -- Repligen Corporation (NASDAQ:RGEN) reported second-quarter revenue that exceeded analyst expectations, driving shares up 5% in pre-market trading as the bioprocessing technology company raised its full-year revenue guidance on strong order momentum.

The company posted revenue of $182 million for the second quarter, surpassing the analyst consensus estimate of $175.35 million and representing a 15% increase compared to the same period last year. Adjusted earnings per share came in at $0.37, slightly below the analyst estimate of $0.39. The company reported 17% organic non-COVID growth, with strength across both consumables and capital equipment segments.

"We had another outstanding quarter in Q2 with 17% organic non-COVID growth. We are very pleased with the momentum we see across the portfolio," said Olivier Loeillot, President and Chief Executive Officer of Repligen. "Orders grew over 20%, which represented the eighth quarter in a row of orders exceeding non-COVID revenue and the fifth quarter of sequential order growth."

The company’s performance was broad-based, with all franchises posting YoY growth. Consumables grew more than 20%, while capital equipment increased in the high-teens. Biopharma revenue grew 20%, and all geographic regions saw mid-teens growth.

Repligen raised its full-year 2025 revenue guidance to a range of $715-735 million, up from the previous consensus of $710.2 million. The company also updated its adjusted earnings per share guidance to $1.65-$1.72, in line with the consensus estimate of $1.68.

The adjusted gross margin for the quarter was 51.1%, unchanged from the same period last year, while the adjusted operating margin was 12.0%, compared to 12.8% in the second quarter of 2024.

Repligen’s cash position remained strong with $709 million in cash, cash equivalents, and short-term investments as of June 30, 2025, compared to $757 million at the end of 2024.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.